Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVCTNASDAQ:PRTCNASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVCTAmerican Virtual Cloud Technologies$0.18$0.97$0.55▼$21.45$5.85M0.055.86 million shsN/APRTCPureTech Health$17.80+1.7%$17.75$13.30▼$26.79$420.33M1.154,714 shs9,305 shsSLNSilence Therapeutics$6.05+4.9%$4.58$1.97▼$22.47N/A1.41302,124 shs131,373 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVCTAmerican Virtual Cloud Technologies0.00%0.00%0.00%0.00%0.00%PRTCPureTech Health-3.62%-9.71%-3.52%-4.20%-38.15%SLNSilence Therapeutics-3.03%+14.03%+14.03%+59.39%-70.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVCTAmerican Virtual Cloud TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APRTCPureTech Health1.8189 of 5 stars3.83.00.00.00.00.00.0SLNSilence Therapeutics2.3351 of 5 stars3.44.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVCTAmerican Virtual Cloud Technologies 0.00N/AN/AN/APRTCPureTech Health 3.50Strong Buy$45.00152.81% UpsideSLNSilence Therapeutics 2.71Moderate Buy$33.83459.23% UpsideCurrent Analyst Ratings BreakdownLatest PRTC, SLN, AVCT, and HZD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.006/13/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.005/9/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$4.00 ➝ $3.005/9/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.005/9/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $35.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVCTAmerican Virtual Cloud Technologies$20.05M0.29N/AN/A$0.17 per share1.06PRTCPureTech Health$4.83M88.52$2.43 per share7.34$17.04 per share1.04SLNSilence Therapeutics$43.26MN/AN/AN/A$4.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVCTAmerican Virtual Cloud Technologies-$161.39MN/A0.00∞N/A-583.38%-8,361.74%-181.35%N/APRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)SLNSilence Therapeutics-$45.31M-$1.50N/AN/AN/A-260.55%-56.17%-33.96%8/15/2025 (Estimated)Latest PRTC, SLN, AVCT, and HZD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SLNSilence Therapeutics-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVCTAmerican Virtual Cloud TechnologiesN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVCTAmerican Virtual Cloud TechnologiesN/A2.292.29PRTCPureTech HealthN/A9.339.33SLNSilence TherapeuticsN/A8.818.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVCTAmerican Virtual Cloud Technologies8.10%PRTCPureTech Health0.04%SLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipAVCTAmerican Virtual Cloud Technologies39.30%PRTCPureTech Health5.30%SLNSilence Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVCTAmerican Virtual Cloud Technologies31632.47 million19.71 millionNot OptionablePRTCPureTech Health10024.02 million22.75 millionNot OptionableSLNSilence Therapeutics100N/AN/ANot OptionablePRTC, SLN, AVCT, and HZD HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to "Hold"June 16, 2025 | americanbankingnews.comSilence Therapeutics' (SLN) "Buy" Rating Reiterated at Chardan CapitalJune 16, 2025 | americanbankingnews.comSilence Therapeutics' (SLN) "Buy" Rating Reaffirmed at HC WainwrightJune 15, 2025 | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Rating Increased to Hold at Wall Street ZenJune 14, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)June 13, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives Buy Rating from Chardan CapitalJune 13, 2025 | marketbeat.comSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraJune 12, 2025 | businesswire.comSilence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from AnalystsJune 7, 2025 | marketbeat.comWall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a BetJune 6, 2025 | zacks.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest UpdateJune 4, 2025 | marketbeat.comMillennium Management LLC Reduces Stock Position in Silence Therapeutics plc (NASDAQ:SLN)June 1, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Shares Acquired by Bank of America Corp DEJune 1, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LPMay 27, 2025 | marketbeat.comWall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to TradeMay 21, 2025 | zacks.comSilence Therapeutics plc GAAP EPS of -C$0.20May 8, 2025 | seekingalpha.comSilence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | finanznachrichten.deSilence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | businesswire.comSilence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are BuyingApril 23, 2025 | insidermonkey.comSilence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare ConferenceMarch 5, 2025 | businesswire.comSilence Therapeutics (SLN) Upgraded to Buy: Here's What You Should KnowMarch 4, 2025 | zacks.comSilence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 1, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTC, SLN, AVCT, and HZD Company DescriptionsAmerican Virtual Cloud Technologies NASDAQ:AVCTAmerican Virtual Cloud Technologies, Inc. engages in the provision of technological solutions. Its products include network communications, data storage, desktops and servers. It operates through the Computex and Kandy segments. The Computex segment provides technology solutions through its extensive hardware, software, and value-added service offerings. The Kandy segment is a provider of cloud-based enterprise services that deploys a carrier grade proprietary cloud communication platform that supports UCaaS, CPaaS, and CCaaS for mid-market and enterprise customers across a proprietary scalable cloud platform. The company was founded on April 7, 2016 and is headquartered in Atlanta, GA.PureTech Health NASDAQ:PRTC$17.50 +0.00 (+0.03%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Silence Therapeutics NASDAQ:SLN$6.05 +0.28 (+4.85%) Closing price 04:00 PM EasternExtended Trading$6.30 +0.25 (+4.05%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
